How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Infectious Disease Archives

A Legacy of American Goodwill and Influence

Integrated Hepatitis C Care in Syringe Service Programs Improves Outcomes for People Who Inject Drugs

The Impact of the Pandemic on Antimicrobial Resistance

Pfizer-BioNTech Vaccine Cuts Long COVID Risk by Up to 20x in Children

The Outbreak the US Got Bored With

CDC Reports 800 Confirmed Measles Cases Across the US

Top 5 Infectious Disease New Stories Week of April 18-April 25

Anticipated Phase 3 Trial of Hydronidone for Treating Liver Fibrosis in Chronic Hepatitis B

Panther’s Microarray Patch Offers Novel Therapy Delivery System for Potential Infectious Disease Applications

Candida auris Epidemiology and Resistance Mechanisms Challenge Antifungal Treatment and Surveillance

Schedule an Appointment

Quick Links

Patient Forms

Contact Us